Literature DB >> 28689852

Development of an integrated cognitive behavioral therapy for anxiety and opioid use disorder: Study protocol and methods.

R Kathryn McHugh1, Victoria R Votaw2, David H Barlow3, Garrett M Fitzmaurice4, Shelly F Greenfield5, Roger D Weiss5.   

Abstract

Opioid use disorder is a highly disabling psychiatric disorder, and is associated with both significant functional disruption and risk for negative health outcomes such as infectious disease and fatal overdose. Even among those who receive evidence-based pharmacotherapy for opioid use disorder, many drop out of treatment or relapse, highlighting the importance of novel treatment strategies for this population. Over 60% of those with opioid use disorder also meet diagnostic criteria for an anxiety disorder; however, efficacious treatments for this common co-occurrence have not be established. This manuscript describes the rationale and methods for a behavioral treatment development study designed to develop and test an integrated cognitive-behavioral therapy for those with co-occurring opioid use disorder and anxiety disorders. The aims of the study are (1) to develop and pilot test a new manualized cognitive behavioral therapy for co-occurring opioid use disorder and anxiety disorders, (2) to test the efficacy of this treatment relative to an active comparison treatment that targets opioid use disorder alone, and (3) to investigate the role of stress reactivity in both prognosis and recovery from opioid use disorder and anxiety disorders. Our overarching aim is to investigate whether this new treatment improves both anxiety and opioid use disorder outcomes relative to standard treatment. Identifying optimal treatment strategies for this population are needed to improve outcomes among those with this highly disabling and life-threatening disorder.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anxiety disorders; Co-occurring disorders; Cognitive-behavioral therapy; Opioid use disorder; Stress reactivity

Mesh:

Year:  2017        PMID: 28689852      PMCID: PMC5553551          DOI: 10.1016/j.cct.2017.07.006

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  64 in total

1.  Hypothalamic-pituitary-adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug cue-induced cocaine craving states.

Authors:  Rajita Sinha; Makram Talih; Robert Malison; Ned Cooney; George M Anderson; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

2.  A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence.

Authors:  Roger D Weiss; Margaret L Griffin; Monika E Kolodziej; Shelly F Greenfield; Lisa M Najavits; Dennis C Daley; Heidi Ray Doreau; John A Hennen
Journal:  Am J Psychiatry       Date:  2007-01       Impact factor: 18.112

3.  Emotional distress tolerance across anxiety disorders.

Authors:  Natalie M Michel; Karen Rowa; Lisa Young; Randi E McCabe
Journal:  J Anxiety Disord       Date:  2016-04-30

4.  Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group.

Authors: 
Journal:  Psychol Med       Date:  1998-05       Impact factor: 7.723

5.  Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders.

Authors:  Stephen T Tiffany; Lawrence Friedman; Shelly F Greenfield; Deborah S Hasin; Ron Jackson
Journal:  Addiction       Date:  2011-10-07       Impact factor: 6.526

6.  Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Kevin P Conway; Wilson Compton; Frederick S Stinson; Bridget F Grant
Journal:  J Clin Psychiatry       Date:  2006-02       Impact factor: 4.384

7.  Childhood social environment, emotional reactivity to stress, and mood and anxiety disorders across the life course.

Authors:  Katie A McLaughlin; Laura D Kubzansky; Erin C Dunn; Robert Waldinger; George Vaillant; Karestan C Koenen
Journal:  Depress Anxiety       Date:  2010-12       Impact factor: 6.505

8.  Motivations for non-medical prescription drug use: a mixed methods analysis.

Authors:  Khary K Rigg; Gladys E Ibañez
Journal:  J Subst Abuse Treat       Date:  2010-07-29

9.  Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.

Authors:  Jessica A Dreifuss; Margaret L Griffin; Katherine Frost; Garrett M Fitzmaurice; Jennifer Sharpe Potter; David A Fiellin; Jeffrey Selzer; Mary Hatch-Maillette; Susan C Sonne; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2013-01-18       Impact factor: 4.492

10.  Anxiety sensitivity: a unique predictor of dropout among inner-city heroin and crack/cocaine users in residential substance use treatment.

Authors:  C W Lejuez; Michael J Zvolensky; Stacey B Daughters; Marina A Bornovalova; Autumn Paulson; Matthew T Tull; Kenneth Ettinger; Michael W Otto
Journal:  Behav Res Ther       Date:  2008-03-28
View more
  7 in total

Review 1.  Comorbidity of opioid-related and anxiety-related symptoms and disorders.

Authors:  Kirsten J Langdon; Kathrine Dove; Susan Ramsey
Journal:  Curr Opin Psychol       Date:  2019-01-04

2.  Randomized controlled trial of telephone monitoring with psychiatry inpatients with co-occurring substance use and mental health disorders.

Authors:  Christine Timko; Alex H S Harris; Mary Jannausch; Mark Ilgen
Journal:  Drug Alcohol Depend       Date:  2018-10-29       Impact factor: 4.492

3.  Psychiatric comorbidity and order of condition onset among patients seeking treatment for chronic pain and opioid use disorder.

Authors:  Declan T Barry; Mark Beitel; Christopher J Cutter; David A Fiellin; Lynn M Madden; Nathan Lipkind; Pooja Bollampally; Christopher Liong; Richard S Schottenfeld
Journal:  Drug Alcohol Depend       Date:  2021-02-15       Impact factor: 4.492

4.  Prevalence of childhood maltreatment among people with opioid use disorder: A systematic review and meta-analysis.

Authors:  Thomas Santo; Gabrielle Campbell; Natasa Gisev; Lucy Thi Tran; Samantha Colledge; Gian Luca Di Tanna; Louisa Degenhardt
Journal:  Drug Alcohol Depend       Date:  2020-12-20       Impact factor: 4.492

Review 5.  A Narrative Literature Review of the Epidemiology, Etiology, and Treatment of Co-Occurring Panic Disorder and Opioid Use Disorder.

Authors:  Ashton E Clark; Shelby R Goodwin; Russell M Marks; Annabelle M Belcher; Emily Heinlein; Melanie E Bennett; Daniel J O Roche
Journal:  J Dual Diagn       Date:  2021-09-28

6.  Effectiveness of teaching cognitive-behavioral techniques on locus of control in hemodialysis patients.

Authors:  Mohammad Mehrtak; Shahram Habibzadeh; Esmaeil Farzaneh; Abdollah Rjaei-Khiavi
Journal:  Electron Physician       Date:  2017-10-25

7.  Advancing preventive interventions for pregnant women who are opioid using via the integration of addiction and mental health research.

Authors:  Kristen L Mackiewicz Seghete; Alice M Graham; Taylor M Shank; Shelby L Alsup; Philip A Fisher; Anna C Wilson; Sarah W Feldstein Ewing
Journal:  Curr Addict Rep       Date:  2020-01-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.